World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
163
Citations
140168
World Ranking
670
National Ranking
386

Richard A. Larson publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Richard A. Larson sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,064 publications — 95th percentile

95% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Richard A. Larson D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Richard A. Larson sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 163 D-Index — 97th percentile

97% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Richard A. Larson is affiliated with the University of Chicago in the United States. Their academic work is concentrated primarily in the field of Medicine, with a particular emphasis on hematology, genetics, public health, oncology, and molecular biology.

Their research covers several subfields, including:

  • Hematology
  • Genetics
  • Public Health, Environmental and Occupational Health
  • Oncology
  • Molecular Biology

Richard A. Larson has contributed extensively to topics within leukemia research and treatment. Main topics of their work include:

  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Acute Lymphoblastic Leukemia research
  • Chronic Lymphocytic Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • CAR-T cell therapy research
  • Hematopoietic Stem Cell Transplantation

The scientist has published in prominent venues frequently associated with hematology and oncology. The leading publication venues include:

  • Blood
  • Blood Advances
  • Leukemia
  • Clinical Lymphoma Myeloma & Leukemia
  • Journal of Clinical Oncology

Some recent notable papers authored by or connected with Richard A. Larson include:

  • Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN, 2022, published in Blood
  • International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data, 2022, published in Blood
  • European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia, 2020, published in Leukemia
  • Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis, 2021, published in Leukemia
  • Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin, 2021, published in Blood

Frequent collaborators in their research include:

  • Wendy Stock
  • Richard M. Stone
  • Olatoyosi Odenike
  • Anand Patel
  • Jorge E. Cortés

The focus of their work spans from basic science in molecular biology to clinical implications in leukemia treatment and public health, indicating a broad and interdisciplinary approach to hematologic malignancies and therapies.

Best Publications

  • Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

    Hartmut Döhner;Elihu Estey;David Grimwade;Sergio Amadori

  • Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

    Stephen G. O'Brien;François Guilhot;Richard A. Larson;Insa Gathmann

  • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

    Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann

  • Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

    Hartmut Dohner;Elihu H. Estey;Sergio Amadori;Frederick R. Appelbaum

  • Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

    Bruce D. Cheson;John M. Bennett;Kenneth J. Kopecky;Thomas Büchner

  • European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

    Michele Baccarani;Michael W. Deininger;Gianantonio Rosti;Andreas Hochhaus

  • The antioxidants of higher plants

    Richard A. Larson

  • Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

    John C. Byrd;Krzysztof Mrózek;Richard K. Dodge;Andrew J. Carroll

  • Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B

    Lewis R. Silverman;Erin P. Demakos;Bercedis L. Peterson;Alice B. Kornblith

  • Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

    Giuseppe Saglio;Dong-Wook Kim;Surapol Issaragrisil;Gabriel Etienne

  • Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

    Richard M. Stone;Sumithra J. Mandrekar;Ben L. Sanford;Kristina Laumann

  • Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

    Michele Baccarani;Giuseppe Saglio;John Goldman;Andreas Hochhaus

  • Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

    Michele Baccarani;Jorge Cortes;Fabrizio Pane;Dietger Niederwieser

  • Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study

    Charles L. Sawyers;Andreas Hochhaus;Eric Feldman;John M. Goldman

  • Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

    Kanti R. Rai;Bercedis L. Peterson;Frederick R. Appelbaum;Jonathan Kolitz

  • FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N 6-Methyladenosine RNA Demethylase

    Zejuan Li;Hengyou Weng;Hengyou Weng;Rui Su;Xiaocheng Weng;Xiaocheng Weng

  • Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.

    Max S. Topp;Nicola Gökbuget;Anthony S. Stein;Gerhard Zugmaier

  • European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

    Andreas Hochhaus;Michele Baccarani;Richard T. Silver;Charles A. Schiffer

  • Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse

    Eric L. Sievers;Richard A. Larson;Edward A. Stadtmauer;Elihu Estey

  • Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

    Andreas Hochhaus;Richard A. Larson;François Guilhot;Jerald P. Radich

Frequent Co-Authors

Clara D. Bloomfield
Clara D. Bloomfield The Ohio State University
Bayard L. Powell
Bayard L. Powell Wake Forest University
Richard Stone
Richard Stone Harvard University
Guido Marcucci
Guido Marcucci City Of Hope National Medical Center
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Krzysztof Mrózek
Krzysztof Mrózek The Ohio State University
Lucy A. Godley
Lucy A. Godley University of Chicago
Frederick R. Appelbaum
Frederick R. Appelbaum Fred Hutchinson Cancer Research Center
James W. Vardiman
James W. Vardiman University of Chicago
Jonathan E. Kolitz
Jonathan E. Kolitz Hofstra University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine opens up a range of related online degrees and opportunities in healthcare. Many students start their journey in the field through nursing schools that don't require teas or hesi entrance exams. These programs can make nursing more accessible without the need for standardized test scores.

For those interested in the operational side of healthcare, a health care administration degree online provides a pathway toward management and leadership roles in hospitals and clinics. These programs are designed for flexibility, allowing students to balance study with work commitments.

If you are an RN seeking further career advancement, consider rn to fnp programs. These bridge programs help registered nurses transition into advanced nurse practitioner roles, expanding their scope of practice and earning potential.

Nutrition is another vital component of healthcare. The best online nutrition programs offer specialized education in dietetics and wellness, preparing graduates for careers in clinical nutrition, public health, and food science.

Best Scientists Citing Richard A. Larson

Trending Scientists

Recently Published Articles